癌症免疫疗法的出现通过利用免疫系统的力量对癌症治疗模式产生了变革性影响。然而，实际和精确靶向恶性细胞的挑战仍然存在。为了解决这个问题，工程纳米颗粒 (NP) 因其尺寸小、免疫原性低且易于表面修饰而成为增强免疫治疗干预中靶向药物递送的有前途的解决方案。这篇全面的综述深入探讨了 NP 工程和免疫治疗关系的当代研究，涵盖了广泛的 NP 形态和针对优化肿瘤靶向和增强治疗效果而定制的策略。此外，它强调了纳米颗粒绕过免疫治疗方案中遇到的众多障碍的机制，并探讨了纳米颗粒与已建立的和新型免疫治疗方式共同给药时的综合潜力。最后，该综述评估了纳米颗粒作为免疫治疗药物输送平台的现有局限性，这可能会为这一前景广阔的领域的未来发展奠定道路。© 2024 作者。

The advent of cancer immunotherapy has imparted a transformative impact on cancer treatment paradigms by harnessing the power of the immune system. However, the challenge of practical and precise targeting of malignant cells persists. To address this, engineered nanoparticles (NPs) have emerged as a promising solution for enhancing targeted drug delivery in immunotherapeutic interventions, owing to their small size, low immunogenicity, and ease of surface modification. This comprehensive review delves into contemporary research at the nexus of NP engineering and immunotherapy, encompassing an extensive spectrum of NP morphologies and strategies tailored toward optimizing tumor targeting and augmenting therapeutic effectiveness. Moreover, it underscores the mechanisms that NPs leverage to bypass the numerous obstacles encountered in immunotherapeutic regimens and probes into the combined potential of NPs when co-administered with both established and novel immunotherapeutic modalities. Finally, the review evaluates the existing limitations of NPs as drug delivery platforms in immunotherapy, which could shape the path for future advancements in this promising field.© 2024 The Authors.